Utreglutide

4 papers14 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 1 country

Human trial4

Outcomes

Body weight

downin humans3−6.8%

3 studies

Utreglutide decreases body weight in humans.
“GL0034 significantly reduced body weight and improved glycemic control versus placebo”
Human trial16 weeks
Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)
ADA Scientific Sessions 2026 abstract5 Jun 2026
Utreglutide decreases body weight in humans (-8.9 kg).
“The BW reduction at Week 14 was 8.9 kg which sustained till EoS and was accompanied by 8.5 cm reduction in WC.”
Human trialobesity and MAFLD13 weeksfemalesn = 22
Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study
AHA Scientific Sessions 2025 abstract3 Nov 2025
Utreglutide decreases body weight in humans (-6.8%).
“At visit 11, BW reduction after UTG treatment was 6.8%”
Human trialsubcutaneous10 weeksn = 20
Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study
ADA Scientific Sessions 2025 abstract13 Jun 2025

Waist circumference

downin humans1

1 study

Utreglutide decreases waist circumference in humans.
“reductions in HbA1c, mean daily self-monitored plasma glucose (SMPG), peak glucose concentration after a liquid meal test and waist circumference”
Human trial16 weeks
Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)
ADA Scientific Sessions 2026 abstract5 Jun 2026

HbA1c

downin humans1

1 study